Abstract: An electronic gaming machine (EGM) archway includes a first EGM including at least one first curved display device, the at least one first curved display device defining a first portion of the archway. The EGM archway also includes a second EGM including at least one second curved display device, the at least one second curved display device defining a second portion of the archway, the second EGM spaced apart from and diametrically opposing the first EGM. In addition, the EGM archway includes an overhead display portion including at least one third display device, the at least one third display device defining a third portion of the archway, the overhead display portion extending overhead between the at least one first curved display device and the at least one second curved display device.

Abstract: A process for preparing hydrogenated polyether-modified amino-functional polybutadienes includes: reacting at least one polybutadiene with at least one epoxidizing reagent to give at least one epoxy-functional polybutadiene; reacting the at least one epoxy-functional polybutadiene with at least one amino-functional compound to give at least one hydroxy- and amino-functional polybutadiene; reacting the at least one hydroxy- and amino-functional polybutadiene with at least one epoxy-functional compound to give at least one polyether-modified amino-functional polybutadiene; and hydrogenating the at least one polyether-modified amino-functional polybutadiene to give at least one hydrogenated polyether-modified amino-functional polybutadiene.

Abstract: The present invention relates to a process for depositing a metal layer on a substrate by contacting the substrate with a metal plating bath comprising a metal ion source and a suppressor, and applying a current density to the substrate, where the suppressor is a polycarboxylate ether as described below. The invention further relates to a metal plating bath comprising a metal ion source and the suppressor which is a polycarboxylate ether; and to a use of the polycarboxylate ether in a metal plating bath for depositing a metal layer on a substrate.

Abstract: A process for preparing hydrogenated polyether-modified polybutadienes includes: reacting at least one polybutadiene with at least one epoxidizing reagent to give at least one epoxy-functional polybutadiene; reacting the at least one epoxy-functional polybutadiene with at least one hydroxy-functional compound to give at least one hydroxy-functional polybutadiene; reacting the at least one hydroxy-functional polybutadiene with at least one epoxy-functional compound to give at least one polyether-modified polybutadiene; and hydrogenating the at least one polyether-modified polybutadiene to give at least one hydrogenated polyether-modified polybutadiene.

Abstract: An operating unit for operating a plurality of functional units of a motor vehicle includes a screen display unit and an input unit. The input unit has at least two selection elements for selecting one of the functional units and has a setting element for making a setting on a selected functional unit. Furthermore, the operating unit is configured to display a setting state of a selected functional unit as a pop-up on the screen display unit. A method of setting a parameter of a functional unit of a motor vehicle is also provided.

Abstract: The present disclosure relates to a vehicle seat cover designated for a detachable attachment to a headrest of a vehicle seat. The vehicle seat cover comprises a pliable first layer with a first recess and a pliable second layer with a first recess, the recesses being configured for accommodating the headrest rod. The recesses each have an edge opening. In the state of the vehicle seat cover attached to the headrest rod one edge opening is partially or completely covered by an edge which limits the other recess.

Abstract: A screen operating unit for a motor vehicle comprises a touch screen an includes two screen areas and an optionally displayable selection area. A functional unit of the motor vehicle can be operated by the screen areas. Alternatively or additionally, graphical contents associated with the functional unit can be depicted. The screen operating unit is configured to make a desired functional unit operable via one of the screen areas and/or to depict graphical contents of the desired functional unit in one of the screen areas. In addition, a method activates an operability of a functional unit of a motor vehicle and/or of activates a depiction of graphical contents associated with the functional unit.

Abstract: An operating unit for operating a plurality of functional units of a motor vehicle includes a screen display unit and an input unit. The input unit has at least two selection elements for selecting one of the functional units and has a setting element for making a setting on a selected functional unit. Furthermore, the operating unit is configured to display a setting state of a selected functional unit as a pop-up on the screen display unit. A method of setting a parameter of a functional unit of a motor vehicle is also provided.

Abstract: The present disclosure relates to a vehicle seat cover designated for a detachable attachment to a headrest of a vehicle seat. The vehicle seat cover comprises a pliable first layer with a first recess and a pliable second layer with a first recess, the recesses being configured for accommodating the headrest rod. The recesses each have an edge opening. In the state of the vehicle seat cover attached to the headrest rod one edge opening is partially or completely covered by an edge which limits the other recess.

Abstract: The present invention provides a method of inhibiting a member of a family of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTP?, PTP?, PTP?, PTP?, PTP?, PTP?, PTP?, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP by exposing said Ptpase member by administration to a host or otherwise to at least one compound with certain structural, physical and spatial characteristics that allow for the interaction of said compound with specific residues of the active site of PTP1B and/or TC-PTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes, as well as in the isolation of PTPases and in elucidation or further elucidation of their biological function.

Abstract: Disclosed are novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTP?, LAR and HePTP or the like, wherein n, m, X, Y, R1, R2, R3, R4, R5 and R6 are defined more fully in the description. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.

Abstract: The present invention relates to methods of preparing compounds of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R4, and R7 have any of the values as defined in the specification. The compounds are useful as agents in the treatment of diseases, including inflammatory diseases such as rheumatoid arthritis. Also provided are compositions of crystalline 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2R-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide comprising less than 2.5% residual organic solvent, and methods for preparing said compositions. Further provided are methods for crystallizing 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2R-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide.

Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP?, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

Abstract: The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, wherein X, R1, R2, R3, and R4 are defined more fully in the description. The compounds are useful in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.

Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like.

Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like.

Abstract: The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, 1

Abstract: The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP (TC-PTP), 1

Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B. CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.